Detection of promoter hypermethylation of Wnt antagonist genes in fecal samples for diagnosis of early colorectal cancer

Table 1 Correlation of the methylation status of fecal SFRP2 and WIF-1 genes with patients’ clinicopathological parameters n (%)

Parameter	Case	WIF-1		SFRP2		WIF-1+SFRP2		Sensitivity	Specificity
	(n)	Methylation	Pvalue	Methylation	Pvalue	Methylation	Pvalue
CRC	48	27 (56.3)	0.0001	29 (60.4)	0.0001	39 (81.3)	0.0001	81.3%
Gender
Male	24	17 (70.8)	0.140	14 (58.3)	0.771
Female	24	12 (29.2)		13 (54.2)
Age (yr)
> 55	32	21 (65.6)	0.297	18 (56.3)	1.000
≤ 55	16	8 (50)		9 (56.3)
Tumor location
Left colon	32	21 (65.6)	0.267	18 (56.3)	1.000
Right colon	16	8 (50)		9 (56.3)
TNM stage
A-B	27	18 (66.7)	0.315	15 (55.6)	0.912
C-D	21	11 (52.4)		12 (57.1)
Lymph node metastasis
Positive	21	11 (52.4)	0.315	12 (57.1)	0.912
Negative	27	18 (66.7)		15 (55.6)
Distant metastasis
Positive	7	4 (57.1)	0.848	4 (57.1)	0.959
Negative	41	25 (61.0)		23 (56.1)
Adenoma	35	18 (51.4)	0.0001	16 (45.7)	0.0001	23 (65.7)	0.0001	65.7%
Advanced	15
Non-advanced	20
Hyperplastic polyp	32	4 (12.5)	0.0451	6 (18.7)	0.0551	8 (25.0)	0.0161	25.0%	96.7%
Normal control	30	0 (0)		1 (3.3)		1 (3.3)

¹Represents the P value vs normal subjects. Sensitivity represents the ability of the DNA methylation test to detect the presence of at least one hypermethylated gene. CRC: Colorectal cancer; SFRP: Secreted frizzled related protein; WIF-1: Wnt inhibitory factor-1.